Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Alessia Maiorino"'
Publikováno v:
Global & Regional Health Technology Assessment, Vol 8 (2021)
Background: Interleukin (IL) inhibitors achieve greater levels of efficacy than older systemic therapies. We calculated the number needed to treat (NNT) of ixekizumab compared with other IL inhibitors approved in Italy for the treatment of moderate-t
Externí odkaz:
https://doaj.org/article/0ee066a17d7f40bc8cb07526059eb545
Publikováno v:
Global & Regional Health Technology Assessment, Vol 6, Iss 1 (2019)
Externí odkaz:
https://doaj.org/article/b15c8206b02b4d86989c8991ead1b867
Publikováno v:
Global & Regional Health Technology Assessment, Vol 2019 (2019)
This analysis was aimed at estimating the cost per responder as measured by number needed to treat of ixekizumab as compared with other biologic drugs approved in Italy for the treatment of moderate-to-severe plaque psoriasis. The clinical efficacy w
Externí odkaz:
https://doaj.org/article/3865e7c1e5b34a9d8e11e4532f60129d
Publikováno v:
Global & Regional Health Technology Assessment, Vol 8 (2021)
Background: Interleukin (IL) inhibitors achieve greater levels of efficacy than older systemic therapies. We calculated the number needed to treat (NNT) of ixekizumab compared with other IL inhibitors approved in Italy for the treatment of moderate-t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fb53109ec5ab947ca3844c74048203d
https://doi.org/10.33393/grhta.2021.2222
https://doi.org/10.33393/grhta.2021.2222
Autor:
Valentina Perrone, Serena Losi, Alessia Maiorino, Silvia Antonelli, Massimo Giovannitti, Elisa Giacomini, Diego Sangiorgi, Luca Degli Esposti
Publikováno v:
Drugs - real world outcomes. 9(2)
Real-world data can inform the use of biologics for psoriasis (PSO).The aim was to evaluate treatment patterns and analyze pharmacoutilization in PSO patients in a real-world Italian setting, with a focus on the biologics most recently introduced.An
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8140a65a487d82f858eb46cfa5de0ee3
https://pubmed.ncbi.nlm.nih.gov/35041194
https://pubmed.ncbi.nlm.nih.gov/35041194
Clinical predictors of nonresponse to anti-TNF-α agents in psoriatic patients: A retrospective study
Autor:
Irene Campana, Alessia Maiorino, Giacomo Caldarola, Francesco Tassone, Clara De Simone, Pietro Sollena, Ketty Peris
Publikováno v:
Dermatologic Therapy. 29:372-376
Although the heterogeneity of the therapeutic response to TNF-α blockers seems to be mainly due to genetic factors, several studies showed that a range of factors may influence it. The aim of our study was to investigate the impact of patients' demo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::87ec24f757f21c869d67ea2b7f05a472
https://doi.org/10.1111/dth.12364
https://doi.org/10.1111/dth.12364
Publikováno v:
Global & Regional Health Technology Assessment, Vol 2019 (2019)
This analysis was aimed at estimating the cost per responder as measured by number needed to treat of ixekizumab as compared with other biologic drugs approved in Italy for the treatment of moderate-to-severe plaque psoriasis. The clinical efficacy w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82c6a5effe68de815a118c3043e6a8f2
https://doaj.org/article/3865e7c1e5b34a9d8e11e4532f60129d
https://doaj.org/article/3865e7c1e5b34a9d8e11e4532f60129d
Publikováno v:
Journal of the European Academy of Dermatology and Venereology. 27:1003-1006
Background Despite recent advances in the treatment of psoriasis, the therapeutic options for nail psoriasis are very limited, particularly when this is the only manifestation of the disease. Objective We performed a randomized controlled open-label
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9fc6c1fd5bcd2c5e2d247c8e671c5833
https://doi.org/10.1111/j.1468-3083.2012.04642.x
https://doi.org/10.1111/j.1468-3083.2012.04642.x
Publikováno v:
The Journal of dermatological treatment. 27(5)
The carcinogenic effect of plus ultraviolet A (PUVA)-therapy in psoriatic patients has been widely demonstrated, while data on the safety of narrow band (311 nm) ultraviolet B (nb-UVB) are scarce. We investigated the occurrence of melanoma and non-me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::944c0fe1eb7fe1c7e92c68c305d46482
https://pubmed.ncbi.nlm.nih.gov/26822468
https://pubmed.ncbi.nlm.nih.gov/26822468
